Cargando…
Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb
Ebola virus (EBOV) is one of the most lethal filoviruses, with mortality rates of up to 90% in humans. Previously, we demonstrated 100% and 50% survival of EBOV-infected cynomologus macaques with a combination of 3 EBOV-GP-specific monoclonal antibodies (ZMAb) administered at 24 or 48 hours post-exp...
Autores principales: | Qiu, Xiangguo, Audet, Jonathan, Wong, Gary, Fernando, Lisa, Bello, Alexander, Pillet, Stéphane, Alimonti, Judie B., Kobinger, Gary P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842534/ https://www.ncbi.nlm.nih.gov/pubmed/24284388 http://dx.doi.org/10.1038/srep03365 |
Ejemplares similares
-
Molecular Characterization of the Monoclonal Antibodies Composing ZMAb: A Protective Cocktail Against Ebola Virus
por: Audet, Jonathan, et al.
Publicado: (2014) -
Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents
por: Wong, Gary, et al.
Publicado: (2014) -
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp(™)
por: Qiu, Xiangguo, et al.
Publicado: (2014) -
Ebola GP-Specific Monoclonal Antibodies Protect Mice and Guinea Pigs from Lethal Ebola Virus Infection
por: Qiu, Xiangguo, et al.
Publicado: (2012) -
Euthanasia Assessment in Ebola Virus Infected Nonhuman Primates
por: Warren, Travis K., et al.
Publicado: (2014)